In situ vaccination with Flt3L, radiotherapy and Poly-ICLC mediates regression of distant lesions in patients with lymphoma26, and a clinical trial with anti-PD-1 therapy is under way for patients including breast cancer (NCT03789097). The gene discussed is FLT3LG; the disease is breast carcinoma.